Mara Rosenberg
Auto-generated profile, based on publicly available information

Mara Rosenberg

Division of Geriatrics, Department of Medicine University of California San Francisco California USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2020 in Nature
Verified
Journal Article
Open access
PDF file
Taobo HuTaobo Hu
Taobo Hu
LALauri A. Aaltonen
Lauri A. Aaltonen
FAFederico Abascal
Federico Abascal
AAAdam Abeshouse
Adam Abeshouse
HAHiroyuki Aburatani
Hiroyuki Aburatani
CMChristian von Mering
Christian von Mering
Cancer is driven by genetic change, and the advent of massively parallel sequencing has enabled systematic documentation of this variation at the whole-genome scale1–3. Here we report the integrative analysis of 2,658 whole-cancer genomes and their matching normal tissues across 38 tumour types from the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA). We describe the generation of the PCAWG resource, facilitated by international data sharing using compute clouds. On average, cancer genomes contained 4–5 driver mutations when combining coding and non-coding genomic elements; however, in around 5% of cases no drivers were identified, suggesting that cancer driver discovery is not yet complete. Chromothripsis, in which many clustered structural variants arise in a single catastrophic event, is frequently an early event in tumour evolution; in acral melanoma, for example, these events precede most somatic point mutations and affect several cancer-associated genes simultaneously. Cancers with abnormal telomere maintenance often originate from tissues with low replicative activity and show several mechanisms of preventing telomere attrition to critical levels. Common and rare germline variants affect patterns of somatic mutation, including point mutations, structural variants and somatic retrotransposition. A collection of papers from the PCAWG Consortium describes non-coding mutations that drive cancer beyond those in the TERT promoter4; identifies new signatures of mutational processes that cause base substitutions, small insertions and deletions and structural variation5,6; analyses timings and patterns of tumour evolution7; describes the diverse transcriptional consequences of somatic mutation on splicing, expression levels, fusion genes and promoter activity8,9; and evaluates a range of more-specialized features of cancer genomes8,10–18.

1 October 2014 in Cell
Verified
Journal Article
Open access
NANishant Agrawal
Nishant Agrawal
RARehan Akbani
Rehan Akbani
BAB. Arman Aksoy
B. Arman Aksoy
AAAdrian Ally
Adrian Ally
HAHarindra Arachchi
Harindra Arachchi
LZLihua Zou
Lihua Zou
Papillary thyroid carcinoma (PTC) is the most common type of thyroid cancer. Here, we describe the genomic landscape of 496 PTCs. We observed a low frequency of somatic alterations (relative to other carcinomas) and extended the set of known PTC driver alterations to include EIF1AX, PPM1D, and CHEK2 and diverse gene fusions. These discoveries reduced the fraction of PTC cases with unknown oncogenic driver from 25% to 3.5%. Combined analyses of genomic variants, gene expression, and methylation demonstrated that different driver groups lead to different pathologies with distinct signaling and differentiation characteristics. Similarly, we identified distinct molecular subgroups of BRAF-mutant tumors, and multidimensional analyses highlighted a potential involvement of oncomiRs in less-differentiated subgroups. Our results propose a reclassification of thyroid cancers into molecular subtypes that better reflect their underlying signaling and differentiation properties, which has the potential to improve their pathological classification and better inform the management of the disease.

1 August 2017 in Cancer Cell
Verified
Journal Article
Open access
BRBenjamin J. Raphael
Benjamin J. Raphael
RHRalph Hruban
Ralph Hruban
AAAndrew J. Aguirre
Andrew J. Aguirre
RMRichard Moffitt
Richard Moffitt
JYJen Jen Yeh
Jen Jen Yeh
JZJean C. Zenklusen
Jean C. Zenklusen
We performed integrated genomic, transcriptomic, and proteomic profiling of 150 pancreatic ductal adenocarcinoma (PDAC) specimens, including samples with characteristic low neoplastic cellularity. Deep whole-exome sequencing revealed recurrent somatic mutations in KRAS, TP53, CDKN2A, SMAD4, RNF43, ARID1A, TGFβR2, GNAS, RREB1, and PBRM1. KRAS wild-type tumors harbored alterations in other oncogenic drivers, including GNAS, BRAF, CTNNB1, and additional RAS pathway genes. A subset of tumors harbored multiple KRAS mutations, with some showing evidence of biallelic mutations. Protein profiling identified a favorable prognosis subset with low epithelial-mesenchymal transition and high MTOR pathway scores. Associations of non-coding RNAs with tumor-specific mRNA subtypes were also identified. Our integrated multi-platform analysis reveals a complex molecular landscape of PDAC and provides a roadmap for precision medicine.

30 April 2018 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
BCBjoern Chapuy
Bjoern Chapuy
CSChip Stewart
Chip Stewart
ADAndrew J. Dunford
Andrew J. Dunford
JKJaegil Kim
Jaegil Kim
AKAtanas Kamburov
Atanas Kamburov
MSMargaret A. Shipp
Margaret A. Shipp

9 May 2016 in Nature Genetics
Verified
Journal Article
Open access
PDF file
CNCancer Genome Atlas Research Network
Cancer Genome Atlas Research Network
JCJoshua D Campbell
Joshua D Campbell
AAAnton Alexandrov
Anton Alexandrov
JKJaegil Kim
Jaegil Kim
JWJeremiah Wala
Jeremiah Wala
MMMatthew Meyerson
Matthew Meyerson
To compare lung adenocarcinoma (ADC) and lung squamous cell carcinoma (SqCC) and to identify new drivers of lung carcinogenesis, we examined the exome sequences and copy number profiles of 660 lung ADC and 484 lung SqCC tumor–normal pairs. Recurrent alterations in lung SqCCs were more similar to those of other squamous carcinomas than to alterations in lung ADCs. New significantly mutated genes included PPP3CA, DOT1L, and FTSJD1 in lung ADC, RASA1 in lung SqCC, and KLF5, EP300, and CREBBP in both tumor types. New amplification peaks encompassed MIR21 in lung ADC, MIR205 in lung SqCC, and MAPK1 in both. Lung ADCs lacking receptor tyrosine kinase–Ras–Raf pathway alterations had mutations in SOS1, VAV1, RASA1, and ARHGAP35. Regarding neoantigens, 47% of the lung ADC and 53% of the lung SqCC tumors had at least five predicted neoepitopes. Although targeted therapies for lung ADC and SqCC are largely distinct, immunotherapies may aid in treatment for both subtypes.

6 November 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
VAViktor A. Adalsteinsson
Viktor A. Adalsteinsson
GHGavin Ha
Gavin Ha
SFSamuel S. Freeman
Samuel S. Freeman
ACAtish Choudhury
Atish Choudhury
DSDaniel G. Stover
Daniel G. Stover
MMMatthew Meyerson
Matthew Meyerson
Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profiling of tumors from blood but the genome-wide concordance between cfDNA and tumor biopsies is uncertain. Here we report ichorCNA, software that quantifies tumor content in cfDNA from 0.1× coverage whole-genome sequencing data without prior knowledge of tumor mutations. We apply ichorCNA to 1439 blood samples from 520 patients with metastatic prostate or breast cancers. In the earliest tested sample for each patient, 34% of patients have ≥10% tumor-derived cfDNA, sufficient for standard coverage whole-exome sequencing. Using whole-exome sequencing, we validate the concordance of clonal somatic mutations (88%), copy number alterations (80%), mutational signatures, and neoantigens between cfDNA and matched tumor biopsies from 41 patients with ≥10% cfDNA tumor content. In summary, we provide methods to identify patients eligible for comprehensive cfDNA profiling, revealing its applicability to many patients, and demonstrate high concordance of cfDNA and metastatic tumor whole-exome sequencing.